News
HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...
Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...
Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...
Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...
Pharmaceutical Technology on MSN1d
The GLP-1 drug shortage is over. What’s next for the compounders?Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...
StockStory.org on MSN2d
Robinhood, AppLovin, Hims & Hers Health, Sleep Number, and Covenant Logistics Shares Plummet, What You Need To KnowDetailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback